Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms

Reuters

2025/07/08

Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms

Evogene Ltd. has announced the completion of its transaction with ICL Group Ltd., involving the divestiture of the majority of Lavie Bio Ltd.'s activities and assets. This transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, and pipeline of advanced development programs to ICL. Evogene has also transferred its MicroBoost AI for AG platform to ICL. The strategic move aligns with Evogene's strategy to enhance the value of its subsidiaries and technology, while ICL aims to strengthen its position in the ag-biologicals market by integrating Lavie Bio's capabilities with its own expertise and global reach. Existing strategic partnerships and commercial agreements of Lavie Bio remain unaffected and under its ownership.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-002325), on July 08, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2549493205"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549493205\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549493205?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549493205","market":"nz","top_or_hot":-1,"title":"Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVGN\">Evogene Ltd.</a> has announced the completion of its transaction with ICL Group Ltd., involving the divestiture of the majority of Lavie Bio Ltd.'s activities and assets. This transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, and pipeline of advanced development programs to ICL. Evogene has also transferred its MicroBoost AI for AG platform to ICL. The strategic move aligns with Evogene's strategy to enhance the value of its subsidiaries and technology, while ICL aims to strengthen its position in the ag-biologicals market by integrating Lavie Bio's capabilities with its own expertise and global reach. Existing strategic partnerships and commercial agreements of Lavie Bio remain unaffected and under its ownership.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-002325), on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-08 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVGN\">Evogene Ltd.</a> has announced the completion of its transaction with ICL Group Ltd., involving the divestiture of the majority of Lavie Bio Ltd.'s activities and assets. This transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, and pipeline of advanced development programs to ICL. Evogene has also transferred its MicroBoost AI for AG platform to ICL. The strategic move aligns with Evogene's strategy to enhance the value of its subsidiaries and technology, while ICL aims to strengthen its position in the ag-biologicals market by integrating Lavie Bio's capabilities with its own expertise and global reach. Existing strategic partnerships and commercial agreements of Lavie Bio remain unaffected and under its ownership.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-002325), on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002521.SGD","symbol_name":"United Global Resources A Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL5z2dYC:1","article_id":"2549493205","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549493205","pubTimestamp":1751972452,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evogene Ltd. has announced the completion of its transaction with ICL Group Ltd., involving the divestiture of the majority of Lavie Bio Ltd.'s activities and assets. This transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, and pipeline of advanced development programs to ICL. Evogene has also transferred its MicroBoost AI for AG platform to ICL. The strategic move aligns with Evogene's strategy to enhance the value of its subsidiaries and technology, while ICL aims to strengthen its position in the ag-biologicals market by integrating Lavie Bio's capabilities with its own expertise and global reach. Existing strategic partnerships and commercial agreements of Lavie Bio remain unaffected and under its ownership.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999002521.SGD":"United Global Resources A Acc SGD","LU0300736492.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) INC","LU0612318971.USD":"BGF NATURAL RESOURCES \"A5G\" (USD) INC","LU0630314457.HKD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (HKD) ACC","LU1430597077.USD":"BGF NATURAL RESOURCES \"A\" (USD) INC","EVGN":"Evogene Ltd.","BK4093":"化肥与农用药剂","BK4588":"碎股","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0612318385.USD":"BGF NATURAL RESOURCES \"A2\" (USD) ACC","LU0300736062.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0654597011.USD":"BGF NATURAL RESOURCES \"A4G\" (USD) INC","LU0345780950.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) ACC","BK4535":"淡马锡持仓","BK4139":"生物科技","LU0345781412.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) INC","CTVA":"Corteva, Inc."},"translate_title":"Evogene完成将Lavie Bio业务出售给ICL，转让关键技术平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTVA":0.9,"EVGN":0.9},"content_text":"Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms\n    \n\nEvogene Ltd. has announced the completion of its transaction with ICL Group Ltd., involving the divestiture of the majority of Lavie Bio Ltd.'s activities and assets. This transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, and pipeline of advanced development programs to ICL. Evogene has also transferred its MicroBoost AI for AG platform to ICL. The strategic move aligns with Evogene's strategy to enhance the value of its subsidiaries and technology, while ICL aims to strengthen its position in the ag-biologicals market by integrating Lavie Bio's capabilities with its own expertise and global reach. Existing strategic partnerships and commercial agreements of Lavie Bio remain unaffected and under its ownership.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-002325), on July 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}